|1.||Di Marzo, Vincenzo: 27 articles (05/2015 - 03/2002)|
|2.||Cravatt, Benjamin F: 21 articles (09/2014 - 12/2002)|
|3.||Piomelli, Daniele: 20 articles (06/2015 - 08/2002)|
|4.||Fowler, Christopher J: 17 articles (06/2015 - 01/2003)|
|5.||Di Marzo, V: 17 articles (03/2011 - 01/2000)|
|6.||Maccarrone, Mauro: 15 articles (05/2013 - 08/2002)|
|7.||Bifulco, Maurizio: 13 articles (05/2013 - 03/2002)|
|8.||Piomelli, D: 12 articles (10/2015 - 04/2000)|
|9.||Kunos, George: 12 articles (05/2015 - 12/2002)|
|10.||Lichtman, Aron H: 12 articles (09/2014 - 12/2002)|
01/01/2005 - "These findings show that inflammatory mediators significantly increase the excitatory potency and efficacy of anandamide on vanilloid type 1 transient receptor potential receptor, thus, increasing the anandamide concentration in, or around the peripheral terminals of nociceptors might rather evoke than decrease inflammatory heat hyperalgesia."
08/01/2014 - "Daily pretreatment with CB1 agonists or anandamide from day 3 attenuated 5-HT-induced hyperalgesia. "
05/02/2013 - "Administration of the cannabinoid agonist CB1 anandamide (12.5, 25 and 50μg/paw) and the cannabinoid agonist CB2 PEA (5, 10 and 20μg/paw) decreased the PGE2-induced hyperalgesia in a dose-dependent manner. "
06/01/2012 - "HP posttreatment had no effect on mechanical allodynia, whereas spinally injected 2-AG and anandamide were potent drugs."
05/01/2009 - "Neither intraplantar injection of anandamide nor vehicle produced antinociception or hyperalgesia to radiant heat. "
11/01/2012 - "In the present study we reported a novel anticancer effect of anandamide involving the inhibition of epithelial-mesenchymal transition, a process triggered during progression of cancer to invasive state."
01/01/2013 - "Anandamide (AEA), an endogenous ligand of cannabinoid CB1 and CB2 receptors, which also binds transient receptor potential vanilloid type 1 receptor (TRPV1), has been shown to display substantial selective cytotoxicity toward some cancer cell lines in vitro, although the relevant data are not consistent. "
06/01/2010 - "We suggest that the inhibitory effect of anandamide analog on tumor cell proliferation could be related to the inhibition of Ras farnesylation."
12/01/2008 - "Chronic administration of anandamide decreased tumor growth and was associated with increased Wnt 5a expression in vitro and in vivo. "
05/01/2007 - "Thus, our results suggest that anandamide could be involved in the control of cancer growth targeting both tumor cell proliferation and the angiogenic stimulation of the vasculature."
|3.||Migraine Disorders (Migraine)
04/01/2008 - "Anandamide (AEA) potentiates 5-HT1A and inhibits 5-HT2A receptors supporting therapeutic efficacy in acute and preventive migraine treatment. "
02/01/2004 - "Anandamide (AEA) potentiates 5-HT1A and inhibits 5-HT2A receptors supporting therapeutic efficacy in acute and preventive migraine treatment. "
04/01/2011 - "Effects of anandamide in migraine: data from an animal model."
08/01/2015 - "Thus, patients suffering from chronic migraine or medication overuse headache showed alterations in the activity of the arachidonoylethanolamide (AEA) degrading enzyme fatty acid amide hydrolase (FAAH) and a specific AEA membrane transporter, alongside with changes in AEA levels. "
10/01/2015 - "URB937, a peripheral inhibitor of fatty acid amide hydrolase (FAAH)-the enzyme that degrades anandamide, produces analgesia in animal models of pain, but there is no information on its effects in migraine. "
04/01/2013 - "In this review, we will discuss the development of FAAH and MAGL inhibitors and their pharmacological application to investigate the function of anandamide and 2-AG signaling pathways in preclinical models of neurobehavioral processes, such as pain, anxiety, and addiction. "
01/01/2013 - "FAAH-like anandamide transporter (FLAT) regulates anandamide transport for hydrolysis and may be an attractive drug target for pain regulation. "
12/05/2012 - "The data are focused on endogenous spinal mechanisms of pain control by anandamide, and the current and emerging pharmacotherapeutic approaches that benefit from the pharmacological modulation of spinal EC and/or endovanilloid systems under chronic pain conditions will be discussed."
10/01/2012 - "Effects of pain induction and of the drug treatments on levels of arachidonoyl ethanolamide (AEA), palmitoyl ethanolamide (PEA) and oleolyl ethanolamide (OEA) in the spinal cord were determined. "
10/01/2010 - "These results suggest that anandamide-mediated signaling at peripheral CB₁ receptors controls the access of pain-related inputs to the CNS. "
|5.||Breast Neoplasms (Breast Cancer)
11/01/2012 - "In this study we described that the treatment of human breast cancer cells, MDA MB 231 cells, with methyl-F-anandamide reduced protein levels of β-catenin in the cytoplasmic and nuclear fractions inhibiting the transcriptional activation of T Cell Factor (TCF) responsive element (marker for β-catenin signalling). "
09/01/2014 - "Aim of the present work is to investigate if anandamide is able to affect the proangiogenic phenotype of the highly invasive and metastatic breast cancer cells MDA-MB-231. "
09/01/2014 - "Anandamide inhibits breast tumor-induced angiogenesis."
05/01/2013 - "Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells."
11/01/2012 - "As accumulating evidences indicate that the constitutive activation of the canonical Wnt pathway in human breast cancer may highlight a key role for aberrant activation of the β-catenin-TCF cascade and tumour progression, we studied the anandamide effect on the key elements of Wnt pathway in breast cancer cells. "
|2.||fatty-acid amide hydrolase (fatty acid amide hydrolase)
|3.||Cannabinoid Receptors (Cannabinoid Receptor)
|7.||cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)
|9.||Neurotransmitter Agents (Neurotransmitter)
|10.||Lipase (Acid Lipase)
|4.||Drug Therapy (Chemotherapy)
|5.||Fat-Restricted Diet (Diet, Fat Restricted)